On May 16-18, the "23rd China Biologics Conference (CBioPC 2024)" was held in Guangzhou. This is an academic event in the field of biomedicine in China. Zhong Nanshan, recipient of the Order of the Republic and academician of the Chinese Academy of Engineering, Zhang Hui, vice president of the China Academy of Food and Drug Administration, Zhao Bingxiang, general manager of China National Pharmaceutical Group Corporation, and Shao Jingbo, deputy director of Guangzhou Development District Administrative Committee, attended the opening ceremony and delivered speeches. Dr. Wei Zhao, Vice President of Chiatai Tianqing, was invited to attend the conference and introduced the company's experience in pharmacological development of recombinant coagulation factor drugs.

The theme of this conference is biopharmaceutical innovation and public health security, aiming to build biopharmaceutical science and technology capacity with core competitiveness and independent intellectual property rights, vigorously develop new productivity of biopharmaceuticals with Chinese characteristics, and actively promote the construction of "Healthy China" by promoting scientific and technological exchanges, integration of the whole industrial chain, and communication between the government and enterprises as well as industry, academia and research institutes. The construction of "Healthy China". More than 8,000 people attended the meeting, including government departments at all levels, regulatory agencies, industry associations, experts and scholars from domestic and foreign biomedical fields and research institutes, and enterprise representatives.

In the afternoon of May 16th, Dr. Zhao Wei was invited to give a keynote speech on "Pharmacological Development of Recombinant Coagulation Factor Drugs" in the "Recombinant Therapeutic Biologics Session". He said that recombinant human coagulation factor VIII/VIIa is difficult to develop due to its complex protein structure, glycosylation modification and instability. Chiatai Tianqing has successfully developed recombinant human coagulation factor VIII and recombinant human coagulation factor VIIa after more than ten years' efforts, developed the process with independent intellectual property rights, and at the same time carried out multi-batches and comprehensive quality research work, which proved the quality of the products can be controlled.

Chiatai Tianqing Recombinant Human Coagulation Factor VIII for Injection has been approved for marketing in August 2023, and is approved for the prevention of bleeding in hemophilia A patients (congenital deficiency of coagulation factor VIII) aged 12 years and above. In terms of recombinant human coagulation factor VIIa for injection, only one product of Novo Nordisk is currently on the market in China (2004), and there is still a large unmet clinical demand. Chiatai Tianqing has applied for the listing of recombinant human coagulation factor VIIa for injection, which is expected to be the first domestically produced recombinant human coagulation factor VIIa, further enhancing drug accessibility, improving patients' quality of life and benefiting more families.

Dr. Zhao Wei said that the biopharmaceutical industry is a strategic emerging industry related to national economy, people's livelihood and national security. Benefiting from the first-class innovation environment in China, Chiatai Tianqing has carried out a rich product layout in the development of biopharmaceuticals in recent years, and nearly 10 products such as Behmosubimab, a Class 1 innovative drug, have been approved for marketing, and a number of products are in the clinical stage. In the future, Chiatai Tianqing will continue to intensify scientific and technological innovation, accelerate the launch of products, and serve the health needs of the society.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650366773&idx=1&sn=1b018a890578cade7677bd9344280a5c&chksm=885fa682bf282f94d7a4182fefc75064ed0c700d9ffd903ae7009b4c3db64d934f672657b081&mpshare=1&scene=1&srcid=0521wkWmj415t2Ktt8Zbmm9l&sharer_shareinfo=15a1ec0c5a3b9ad5b08f74e547b0e1a2&sharer_shareinfo_first=15a1ec0c5a3b9ad5b08f74e547b0e1a2#rd